Mosaic stock closed up 3.1% at US$23.41, a bounce that might look at odds with another quarter of losses on the income statement. The market is reacting less to the latest earnings loss and more to what the balance sheet and valuation now signal. Mosaic is still unprofitable over the past year, yet the shares trade well below one prominent discounted cash flow fair value estimate and at a low price to sales multiple against peers. The real question for you is how long the company can carry its dividend and debt load while waiting for that potential earnings recovery story to play out.

Like the value case for Mosaic but worried about the earnings losses and dividend risk while you wait? Compare it with list of solid balance sheet and fundamentals stocks (50 results).

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs. Q2 2025): US$2,824.1 million vs. US$3,005.7 million (revenue declined 6.0%)
• Net Income or Loss (Q2 2026 vs. Q2 2025): loss of US$272.8 million vs. profit of US$410.7 million (swung from profit to loss)
• Basic EPS (Q2 2026 vs. Q2 2025): loss of US$0.86 per share vs. profit of US$1.29 per share (earnings per share moved from profit to loss)
• Trailing Twelve Month Net Income or Loss (TTM to Q2 2026 vs. TTM to Q2 2025): loss of US$638.5 million vs. profit of US$940.0 million (moved from profitability to a trailing loss)

Tired of scrolling through earnings tables and still feeling unsure what Mosaic's story really looks like? Get a clear visual view of Mosaic's valuation, including how the market is pricing the stock against its fundamentals right now, in the full company report for Mosaic.

Mosaic Bull Case Hinges On Execution, Not Story

Bulls argue Mosaic is an operational recovery story where sulfur normalization, a production ramp and higher value products restore margins and cash flow. The latest quarter offers some proof points but also shows how far there is to go. Phosphates still ran at curtailed rates because sulfur costs and flows made full production uneconomic. That means the promised unit cost relief from higher run rates has not yet arrived.

On the positive side, potash remains a steady earner with summer fill fully subscribed, which supports the claim that at least one core segment is already carrying its weight. Mosaic Biosciences is on track to double revenue again this year with strong margins, which backs the idea that higher value products can lift group quality over time. Capital expenditure has been cut to about US$1.2 billion, and liquidity actions also align with a turnaround that prioritizes cash and margin over raw volume.

Compare Mosaic's internal progress on potash, biosciences and capex discipline with how institutional analysts are reacting. See the consensus price target analysis for Mosaic to check whether the current Wall Street targets line up with this recovery pitch.

Bear Concerns On Mosaic Margins Largely Intact

The bearish view on Mosaic centers on the idea that high sulfur and other input costs will keep pressuring phosphate and Fertilizantes profitability and that operational fixes will not arrive quickly enough. Q2 does little to challenge that view. Revenue fell 6.0% year on year while Mosaic moved from a US$410.7 million profit to a US$272.8 million loss, and the trailing twelve month loss of US$638.5 million indicates this is not a single quarter issue.

Bears focus on the risk that sulfur inflation forces Mosaic to curtail output and absorb higher fixed costs. Management explicitly confirmed curtailed phosphate production in the U.S. and Brazil because sulfur costs and flows made full rates uneconomic, and guided to lower fixed cost absorption again in Q3. That represents a missed milestone on cost normalization. Potash and Mosaic Biosciences contribute positively, but they are not yet offsetting phosphate and Fertilizantes pressure at the group level.

After interest coverage and dividend strain, are these margin setbacks just the surface issues? Review our independent risk analysis for Mosaic which shows 2 important warning signs

Stay Ahead With Simply Wall St

If Mosaic's mix of losses, dividend pressure and turnaround potential has your attention, register for free with Simply Wall St and add it to your Watchlist to track price against fair value and watch how the story develops. Once you decide to take a position, use the Portfolio Command Center to cut through noise and focus on the key updates that matter to your holdings. For a broader view, tap into crowd insight and discussion through the Community to see how other investors are thinking about Mosaic and similar stocks. Spot potential catalysts and risks early so you can move faster and stay ahead of the market.

Curious About Alternatives To Mosaic

Fresh ideas can move fast. Some stocks are building breakout momentum while others are still under the radar for now. Check these themes before the crowd and get in early.

• Spot companies quietly building strength in core operations, then compare Mosaic with a curated group of resilient businesses using the 79 resilient stocks with low risk scores.
• Explore potential opportunities linked to structural shifts in global energy and grid demand by scanning a focused list of infrastructure stocks through the 36 power grid technology and infrastructure stocks.
• Focus on companies already showing real revenue traction in artificial intelligence by working through the hand picked shortlist in the 67 profitable AI stocks that aren't just burning cash.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.